Regeneron Pharmaceuticals (REGN) Change in Cash (2009 - 2026)

Regeneron Pharmaceuticals' Change in Cash history runs 18 years deep, the most recent figure standing at -$504.6 million for Q2 2026.

• In Q2 2026, Change in Cash rose 53.17% year-over-year to -$504.6 million; the TTM figure through Jun 2026 stood at $450.4 million (up 415.33% YoY), while the FY2025 annual figure was $634.7 million, up 355.1% from the prior year.
• Change in Cash for Q2 2026 stood at -$504.6 million, down from -$153.1 million in the prior quarter.
• The five-year high for Change in Cash was $809.4 million in Q1 2023, with the low at -$2.0 billion in Q2 2023.
• The 5-year median for Change in Cash is $89.9 million (2022), against an average of -$24.0 million.
• The sharpest annual moves came in 2023 and 2025: Change in Cash plunged 4106.28% in 2023, then jumped 571.88% in 2025.
• Regeneron Pharmaceuticals' Change in Cash stood at -$385.4 million in 2022, then soared by 249.87% to $577.6 million in 2023, then dropped by 17.38% to $477.2 million in 2024, then rose by 27.95% to $610.6 million in 2025, then tumbled by 182.64% to -$504.6 million in 2026.
• Business Quant data shows REGN's Change in Cash at -$504.6 million in Q2 2026, -$153.1 million in Q1 2026, and $610.6 million in Q4 2025.